Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287042 | 0.90 | OPRK1 (0.33) | OPRK1POLBHSD17B10 | |
| SCHEMBL1287069 | 0.83 | CHRM1 (0.35) | OPRK1ALDH1A1GAA | |
| SCHEMBL1287027 | 0.77 | — | — | |
| SCHEMBL1287102 | 0.76 | OPRK1 (0.42) | OPRK1SMN1; SMN2TP53ALDH1A1GAA | |
| SCHEMBL1287037 | 0.75 | OPRK1 (0.50) | OPRK1SMN1; SMN2TP53ALDH1A1GAA | |
| SCHEMBL3073995 | 0.73 | OPRK1 (0.35) | OPRK1POLBSMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1287002 | 0.73 | OPRK1 (0.40) | OPRK1POLBSMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1287001 | 0.73 | OPRK1 (0.40) | OPRK1POLBSMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1287061 | 0.73 | OPRK1 (0.40) | OPRK1POLBSMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1287095 | 0.73 | PLG (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012047156-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS PLASMINOGEN INHIBITORS AND THEIR USE IN THE TREATMENT OF FIBRINOLYSIS RELATED DISEASES | ASTRAZENECA AB (SE) | 2012-04-12 | — | — | WO | disclosed |